Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololBjörn Dahlöf, Hans Wedel, Richard B. Devereux et al.|The Lancet|2002Cited by 5.4k
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololLars Lindholm, Steven Snapinn, Hans Ibsen et al.|The Lancet|2002Cited by 1.6k
Clinical Practice Guidelines for the Management of Hypertension in the CommunityMichael A. Weber, Stephen Harrap, Ernesto L. Schiffrin et al.|Journal of Clinical Hypertension|2013Cited by 1k
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysisKazem Rahimi, Takayoshi Ohkubo, Barry R. Davis et al.|The Lancet|2021Cited by 997
Clinical Practice Guidelines for the Management of Hypertension in the CommunityMichael A. Weber, Stephen Harrap, Ernesto L. Schiffrin et al.|Journal of Hypertension|2013Cited by 685